Soleo Health has been named the exclusive in-network specialty pharmacy for Qfitlia (fitusiran) by Sanofi, the first ...

The US Food and Drug Administration granted clearances for testing instruments, a blood clot drug companion diagnostic test, and infectious disease tests, among other devices.

💊 Sanofi’s Qfitlia (fitusiran) has just received FDA approval - introducing the first siRNA therapy for haemophilia A & B. This innovative treatment helps prevent bleeds and brings real hope ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May ...

While the fourth quarter of 2024 continued the trend seen throughout the year of increasing momentum in FDA new drug approvals, with 16 such approvals handed out, the first quarter of 2025 has ...

The pairing of two Bristol Myers Squibb immunotherapies is now permitted for the first-line treatment of two types of gastrointestinal cancers, after regulatory decisions handed out this past week ...

Sanofi (NASDAQ:SNY) announced Tuesday that its TIDE-Asthma Phase 2 study for its T-cell-depleting monoclonal antibody amlitelimab didn’t reach the primary endpoint for the highest dose level but ...

At 3 years, Opdivo plus Yervoy led to an overall survival rate of 38% in patients with unresectable or metastatic hepatocellular carcinoma, compared to 24% with lenvatinib or sorafenib monotherapy ...

Click here to see the full list of 232 stocks from our US High Growth Tech and AI Stocks screener. Let's review some notable picks from our screened stocks. Alnylam Pharmaceuticals Simply Wall St ...

In 2025, Plozasiran (Arrowhead Pharmaceuticals), Donidalorsen (Ionis Pharmaceuticals) and Fitusiran (Sanofi/Alnylam) are expected to receive approval. All of that is being driven by increasing ...